Skip to main content

Table 1 HPV Prevalence in 34 trials (N = 5681)

From: Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)

Title Patients (n) No. of HPV positive (n) Prevalence HPV % No. of HPV16 (n) Prevalence HPV16 in HPV (%)
Mork rtl, et al. 2001 292 88 30.14% 35 39.77%
D'Souza, et al. 2007 100 40 40.00% 35 87.50%
Gillison, et al. 2000 253 62 24.51% 56 90.32%
Herrero, et al. 2003 1670 56 3.35% 21 37.50%
Smith, et al. 2004 201 46 22.89% 39 84.78%
Braakhuis, et al. 2004 143 24 16.78% 24 100.00%
Fakhry, et al. 2008 96 38 39.58% 36 94.74%
Teman, et al. 2008 105 12 11.43% 0 0.00%
Weinberger, et al. 2006 77 47 61.04% 47 100.00%
Licitra, et al. 2006 90 17 18.89% 17 100.00%
Worden, et al. 2008 66 27 40.91% 27 100.00%
Shindoh, et al. 1995 77 24 31.17% 24 100.00%
Lindel, et al. 2001 99 14 14.14% 11 78.57%
Klussmann, et al. 2001 98 25 25.51% 21 84.00%
Perrone, et al. 2007 77 16 20.78% 16 100.00%
Kutler, et al. 2003 25 21 84.00% 19 90.48%
Smith, et al. 2004 193 38 19.69% 33 86.84%
Baez, et al. 2004 118 52 44.07% 52 100.00%
Dahlgren, et al. 2004 110 12 10.91% 9 75.00%
Hoffmann, et al. 2004 73 28 38.36% 28 100.00%
Slebos, et al. 2006 36 8 22.22% 8 100.00%
Hammarstedt, et al. 2006 203 99 48.77% 86 86.87%
Ragin, et al. 2006 125 30 24.00% 30 100.00%
Reimers, et al. 2007 106 30 28.30% 29 96.67%
Furniss, et al. 2007 486 145 29.84% 145 100.00%
Smith, et al. 2008 301 81 26.91% 77 95.06%
Pintos, et al. 2008 72 14 19.44% 13 92.86%
Charfi, et al. 2008 52 32 61.54% 27 84.38%
Westra, et al. 2008 89 12 13.48% 12 100.00%
Hafkamp, et al. 2008 81 33 40.74% 33 100.00%
Friesland, et al. 2001 34 14 41.18% 14 100.00%
De Petrini, et al. 2006 47 20 42.55% 20 100.00%
Wittekindt, et al. 2005 34 18 52.94% 16 88.89%
Strome, et al. 2002 52 24 46.15% 21 87.50%
  5681 1247 21.95% 1081 86.69%